Main Products ; XTANDI™ (enzalutamide). XTANDI is a treatment for prostate cancer. ; PADCEV™ (enfortumab vedotin). PADCEV is a treatment for urothelial cancer. About · Subsidiaries & Locations · Global Management Structure · Board of Directors

New Portfolio since 2020 · Avilar Therapeutics, Inc (MA, USA) · Casma Therapeutics, Inc (MA, USA) · Carbon Biosciences (MA, USA) · Catamaran Bio, Inc (MA, USA) · DEM ...

Learn about the progress of our clinical development pipeline, which will be updated four or five times each year.

The list shows the development status in the target diseases for which we aim to obtain approval in Japan, the United States, Europe and/or China.

We will make an investment in privately owned early-stage biotechnology company focused on therapeutics programs and platform technologies for drug discovery ...

Astellas Pharma Canada has introduced a variety of novel products into the Canadian market through our own innovations and collaborations with other companies.

Astellas Pharma has 10 portfolio exits. Their latest portfolio exit was Affinivax on May 31, 2022.

Explore the portfolio of Astellas pharma and see who they invested in and when.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative ... Careers at Astellas · Astellas and Sustainability · Access to Health of Astellas · About

Unified Digital Strategy and Portfolio Management: Drive the development of a comprehensive digital strategy that leverages innovations to meet business goals.